A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Recurrent Squamous Cell Carcinoma
Interventions
DEVICE

DaRT seeds

DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.

Trial Locations (31)

11375

SUSPENDED

Northwell Health, Queens

11694

RECRUITING

New York Medical Skin Solutions, Rockaway Park

11787

NOT_YET_RECRUITING

MDCS Dermatology, Smithtown

13326

RECRUITING

Bassett Healthcare Network, Cooperstown

22908

WITHDRAWN

University of Virginia Health System, Charlottesville

30308

RECRUITING

Emory University, Atlanta

32720

RECRUITING

Day Star Skin and Cancer Center, DeLand

33021

RECRUITING

Hollywood Dermatology, Hollywood

33101

RECRUITING

University of Miami, Miami

33176

RECRUITING

Baptist Health South Florida MCI, Miami

33401

NOT_YET_RECRUITING

Beer Dermatology, West Palm Beach

33445

RECRUITING

Integrity Research Clinical Associates, Delray Beach

33484

NOT_YET_RECRUITING

Palm beach Dermatology Group, Delray Beach

NOT_YET_RECRUITING

Palm Beach Dermatology Group, Delray Beach

33612

RECRUITING

Moffitt Cancer Center, Tampa

38138

WITHDRAWN

West Cancer Center, Germantown

55905

RECRUITING

Mayo Clinic Rochester, Rochester

77008

NOT_YET_RECRUITING

Gulf Coast Cancer Center, Houston

77089

RECRUITING

University Cancer & Diagnostic Center, Houston

85004

RECRUITING

Dignity Health Cancer Institute, Phoenix

85032

RECRUITING

Alliance Dermatology, Phoenix

85234

RECRUITING

Banner Health MD Anderson Phoenix, Gilbert

87109

RECRUITING

New Mexico Cancer Center, Albuquerque

90095

RECRUITING

UCLA, Los Angeles

98004

RECRUITING

Dermatology of Seattle and Bellevue, Bellevue

9777605

RECRUITING

Hadassah Medical Center, Jerusalem

07601

NOT_YET_RECRUITING

Schweiger Dermatology Group, Hackensack

Unknown

RECRUITING

Princess Margaret Cancer Center, Toronto

RECRUITING

Rambam Medical Center, Haifa

RECRUITING

Belinson-Rabin Medical Center, Petah Tikva

RECRUITING

Sheba Medical Center, Ramat Gan

Sponsors
All Listed Sponsors
lead

Alpha Tau Medical LTD.

INDUSTRY

NCT05323253 - A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter